Introduction
============

The dopamine transporter (DAT)[^3^](#FN4){ref-type="fn"} is a member of the SLC6 gene family of neurotransmitter:sodium symporters. DAT mediates the reuptake of extracellular dopamine from the synaptic cleft into the presynaptic neuron ([@B1]--[@B3]), thus terminating dopaminergic neurotransmission ([@B4], [@B5]). DAT dysfunction has been associated with various neuropsychiatric diseases such as schizophrenia, Parkinson disease, attention deficit hyperactivity disorder, and drug addiction ([@B6], [@B7]).

DAT is also the primary target of a number of different illicit psychostimulant drugs such as cocaine and amphetamine. Most amphetamines, with the notable exception of methylphenidate, are DAT substrates and thereby induce a reversal of the normal transport process, ultimately resulting in the non-exocytotic transporter-mediated efflux of substrate ([@B8], [@B9]). An increase in the concentration of intracellular sodium is a known prerequisite of transporter reversal ([@B10]). However, the exact mechanistic details of reverse transport remain enigmatic. The role of DAT-interacting proteins in non-exocytotic transporter-mediated efflux has become more and more apparent recently, and they are now believed to be intricately involved in this process ([@B2]). For example, protein kinase Cβ (PKCβ) has previously been described as a regulator of DAT efflux ([@B11], [@B12]), and more recently, it was shown that the serine/threonine kinase Ca^2+^/calmodulin-dependent protein kinase IIα (αCaMKII) binds to the DAT carboxyl terminus and phosphorylates its amino terminus ([@B13]). Furthermore, the pharmacological inhibition of αCaMKII by KN93 attenuates amphetamine-triggered DAT-mediated substrate efflux in human embryonic kidney cells (HEK293) and in rat striatal slices ([@B13]).

Angelman syndrome is a neurogenetic disease that arises from a defective maternally inherited allele in ubiquitin ligase Ube3A ([@B14]). The clinical phenotype of Angelman syndrome (AS) includes movement disorders and autism spectrum disorders, which collectively establish a connection to the dopaminergic system. Elucidating the underlying pathophysiology of Angelman syndrome is of vast therapeutic importance as there is, as yet, no effective pharmacotherapy available. Mice engineered to be maternally Ube3A-deficient (Ube3A^p+/m−^) have previously been used as an animal model of human Angelman syndrome ([@B15]); Ube3A^p+/m−^ causes the accumulation of autoinhibited αCaMKII in the brain ([@B16]). Because αCaMKII binds to the carboxyl terminus of the DAT and phosphorylates its amino terminus ([@B13]) to afford amphetamine-induced efflux ([@B10]), we reasoned that Ube3A^p+/m−^ mice may phenocopy the effect of αCaMKII deficiency on DAT.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Reagents

[d]{.smallcaps}-Amphetamine-sulfate and methylphenidate were purchased from Sigma Aldrich; \[^3^H\]2-carbo-methoxy-3-(4-fluorophenyl)tropane (CFT; 85.9 Ci/mmol) was obtained from PerkinElmer Life Sciences, and \[^3^H\]MPP^+^ (85 Ci/mmol) was provided by American Radiolabeled Chemicals. KN93 and autocamtide-2 related inhibitory peptide II were from Calbiochem. The cell culture media, supplements, and antibiotics were from Invitrogen. The rat anti-dopamine transporter antibody (MAB369) was provided by Millipore. The goat anti-dopamine transporter (C-20), mouse monoclonal anti-αCaMKII, and rabbit polyclonal anti-αCaMKII antibodies were all purchased from Santa Cruz Biotechnology. Mouse anti-α-tubulin (Sigma Aldrich), anti-rat Alexa Fluor 568, the anti-mouse Alexa Fluor 488 (Invitrogen), anti-rat horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technologies), and mouse and rabbit horseradish peroxidase-conjugated antibodies (GE Healthcare) were also used.

#### Animals

The generation of the Ube3A maternally deficient mice (Ube3A^p+/m−^) and of the αCaMKII-knock-out (KO) and αCamKII^T305D^ mice has been described previously ([@B15], [@B17]).

The αCaMKII-KO and αCamKII^T305D^ mice were in the C57BL/6J background, and the Ube3A^p+/m−^ mice were in the 129/Sv background. All experiments were performed using wild-type (WT) control mice of the appropriate genetic background. All experiments were performed *ex vivo*. The mice were bred in the Research Facility for Animal Experimentation (Forschungsanstalt für Versuchstierzucht; Himberg, Austria).

#### Preparation of Mouse Striatal Synaptosomes and Slices

Adult mice were sacrificed by cervical dislocation, and the brains were removed immediately. The striatum was dissected and either homogenized in ice-cold phosphate-buffered saline (PBS) containing 0.32 [m]{.smallcaps} sucrose and protease inhibitors (Roche complete) to prepare synaptosomes or else cut into slices (0.3 mm) using a McIllwain Tissue Chopper. For the preparation of synaptosomes, the suspension was centrifuged for 10 min at 1000 × *g*. The supernatant was again centrifuged for 15 min at 12,600 × *g*. The resulting pellet (P~2~) was weighed and stored on ice until the start of the experiment. Slices were kept in Krebs-HEPES buffer (KHB, 25 mm HEPES; 120 mm NaCl; 5 mm KCl; 1.2 mm CaCl~2~; and 1.2 mm MgSO~4~ supplemented with 5 mm [d]{.smallcaps}-glucose) until the beginning of the experiment.

#### Preparation of Primary Dopaminergic Neurons

Midbrains from 1--3-day-old pups were dissected and cultured as described previously ([@B18]) with slight modifications. Briefly, ventral midbrains were digested in papain for 20 min at 37 °C and triturated afterward to dissociate the cells using increasingly smaller pipette tips. The cells were centrifuged for 4 min at 500 × *g* and resuspended in neuronal medium (Neurobasal A, 2% B27, 1% heat-inactivated calf serum, 0.4 m[m]{.smallcaps} glutamine, 50 μ[m]{.smallcaps} kynurenic acid). The neurons were then seeded onto glial cells grown on coverslips. Glial-derived neurotrophic factor (Millipore) was added to each culture 2 h after seeding to stimulate sprouting and maturation of neurons. 5-Fluorodeoxyuridine was added to inhibit proliferation of glia. Cultures were used for experiments after at least 21 days *in vitro*.

#### Immunocytochemistry

Primary dopaminergic neurons were fixed using 4% paraformaldehyde in PBS for 20 min at room temperature. The neurons were washed 3× with PBS after fixation and blocked for 1 h using blocking/permeabilization buffer (5% goat serum in PBS, including 0.2% saponin). The neurons were then incubated overnight at 4 °C with a rat monoclonal dopamine transporter antibody and a mouse monoclonal αCaMKII antibody in blocking/permeabilization buffer. The next day, the neurons were washed 3× with PBS before being incubated with anti-rat Alexa Fluor 568 and anti-mouse Alexa Fluor 488 for 1 h at room temperature. The neurons were then washed 3× with PBS before being imaged using a Zeiss LSM510 laser scanning confocal microscope.

#### \[^3^H\]CFT Binding

Binding was performed in striatal synaptosomes resuspended in assay buffer (20 m[m]{.smallcaps} Tris/HCl, 2 m[m]{.smallcaps} MgCl~2~, 120 m[m]{.smallcaps} NaCl, 3 m[m]{.smallcaps} KCl; pH 7.4) to a final concentration of 0.3 mg of wet weight per 100 μl. The binding assays were conducted with increasing concentrations of \[^3^H\]CFT, ranging from 1.25 to 40 n[m]{.smallcaps}. Nonspecific binding was determined in the presence of 3 μ[m]{.smallcaps} methylphenidate. The final assay volume was 0.2 ml. Zn^2+^ (final concentration of 10 μ[m]{.smallcaps}) was added to increase the affinity of \[^3^H\]CFT for DAT ([@B19]). The reactions were performed at 22 °C for 10 min. After incubation, the assay tubes were rapidly filtered onto GF/B filters (Whatman) using an automatic cell harvester filtration device (Skatron Instruments AS). Binding was terminated following extensive washing with an ice-cold wash buffer (10 m[m]{.smallcaps} Tris-HCl, 10 m[m]{.smallcaps} MgCl~2~, 120 m[m]{.smallcaps} NaCl, 10 μ[m]{.smallcaps} ZnCl~2~). The radioactivity on the filters was measured by liquid scintillation.

#### \[^3^H\]MPP^+^ Uptake

\[^3^H\]MPP^+^ has been used throughout the study because of its superior signal-to-noise ratio. Due to its fixed charge, MPP^+^ does not permeate the membrane in the absence of transporter-mediated uptake. Accordingly, back-diffusion that may confound the analysis is obviated ([@B20]). \[^3^H\]MPP^+^ uptake (20 n[m]{.smallcaps}) was measured in striatal synaptosomes. P~2~ pellet was resuspended in KHB to yield a final concentration of 0.3 mg of wet weight/50 μl in a final assay volume of 200 μl. The uptake assay was conducted in KHB for 5 min at 37 °C. Nonspecific uptake was determined in the presence of 10 μ[m]{.smallcaps} mazindol. The assay was terminated by the addition of 2.5 ml of ice-cold KHB buffer and rapid filtration through GF/C filters (Whatman) followed by two wash steps. Radioactivity on the filters was measured by liquid scintillation.

#### Superfusion

For superfusion assays, the P~2~ pellets were dissolved in KHB to yield a final concentration of 1 mg of P~2~ pellet in a total volume of 15 μl.

Synaptosomal fractions or slices for superfusions were incubated with 0.1 μ[m]{.smallcaps} \[^3^H\]MPP^+^ (synaptosomes) or 0.4 μ[m]{.smallcaps} \[^3^H\]MPP^+^ (slices) for 20 or 30 min, respectively, at 37 °C. After incubation, 15 μl of the P~2~ suspension was loaded onto GF/B Whatman filters, and these filters were inserted into superfusion chambers. For slice superfusion, one slice was used per chamber. A washout period of 40 min at a flow of 0.7 ml/min (25 °C) was started, and it served to establish a basal efflux of radioactivity. Superfusate samples were collected at 2-min intervals. At min 6, \[^3^H\]MPP^+^-loaded synaptosomes were superfused by either KN93 or dimethyl sulfoxide (vehicle).

At min 12, synaptosomes were challenged by the addition of 6 μ[m]{.smallcaps} [d]{.smallcaps}-amphetamine to induce DAT-mediated efflux. The experiment was stopped at min 20, synaptosomes containing filters or slices were recovered, lysed in 1% SDS, and mixed with scintillation mixture to determine the total amount of radioactivity present at the end of the experiment.

\[^3^H\]MPP^+^ efflux is expressed as percentage of total radioactivity present in each fraction or as area under the curve (AUC). AUC of amphetamine efflux was calculated by adding the total radioactivity present in each fraction upon amphetamine stimulation (*i.e.* min 12--20) and normalizing this sum to the base-line efflux (*i.e.* the mean of min 0--4). The AUC is proportional to substrate efflux.

#### Surface Biotinylation

Synaptosomes were resuspended in Krebs-Ringer bicarbonate (KRB) buffer (24.9 m[m]{.smallcaps} NaHCO~3~, 1.2 m[m]{.smallcaps} KH~2~PO~4~, 146.2 m[m]{.smallcaps} NaCl, 2.7 m[m]{.smallcaps} KCl, 1.0 m[m]{.smallcaps} MgCl~2~, 10 m[m]{.smallcaps} glucose, 50 μ[m]{.smallcaps} ascorbic acid) saturated with 95% O~2~/5% CO~2~ as described previously ([@B12]). 200 μg of synaptosomes were treated with sulfo-NHS-SS-biotin (1 mg/1 mg of protein) in KRB for 30min at 4 °C. This reaction was quenched using 100 m[m]{.smallcaps} glycine in KRB and incubated for 30 min at 4 °C. The synaptosomes were then lysed in lysis buffer (10 m[m]{.smallcaps} Tris-HCl, pH 7.4, 150 m[m]{.smallcaps} NaCl, 1 m[m]{.smallcaps} EDTA, 1% Triton X-100, 0.1% SDS) supplemented with protease inhibitor mixture (Roche complete). The lysates were incubated with streptavidin beads (Thermo Fisher Scientific, Inc.) overnight at 4 °C. The next day, the beads were washed three times with lysis buffer and subsequently subjected to SDS-PAGE.

#### Co-immunoprecipitation of DAT

A crude membrane fraction was prepared from wild-type (C57Bl/6J background) and αCamKII knock-out or wild-type (129/Sv background) and Angelman syndrome striatal tissues. The crude membrane fraction (10 mg) was solubilized in lysis buffer containing 1% Triton X-100, 20 m[m]{.smallcaps} Tris-HCl, pH 8.0, 150 m[m]{.smallcaps} NaCl, 1 m[m]{.smallcaps} EDTA, 1 m[m]{.smallcaps} sodium orthovanadate, 5 m[m]{.smallcaps} NaF, 5 m[m]{.smallcaps} sodium pyrophosphate, and a protease inhibitor mixture (Roche complete) on a tube rotator for 2 h at 4 °C. After centrifugation at 14,000 × *g* for 30 min at 4 °C, the supernatant was collected and incubated overnight with goat anti-DAT polyclonal antibody. After protein G bead (GE Healthcare) incubation and subsequent washing, bound proteins were eluted in SDS sample buffer at 95 °C for 3 min. Eluted proteins were size fractionated on SDS-PAGE gels and visualized by a Coomassie brilliant blue staining.

#### SDS-PAGE and Western Blot

Proteins were loaded onto an SDS-polyacrylamide gel and then transferred onto Protran^TM^ nitrocellulose membranes (Whatman). Membranes were incubated overnight at 4 °C with primary antibodies: rat anti-DAT, goat anti-DAT, rabbit anti-αCaMKII, and mouse anti-α-tubulin.

The bands were visualized using the enhanced chemoluminiscence detection method (Thermo Scientific Pierce). Densitometric quantification of the bands was performed by NIH ImageJ software (Image Processing and Analysis in Java).

#### In-gel Digestion

The Coomassie Blue-stained bands were directly excised from SDS-PAGE gel, destained with 50% acetonitrile in 25 m[m]{.smallcaps} ammonium bicarbonate, and dried in a speed vacuum concentrator. After reduction and alkylation of cysteine residues, gel pieces were washed and dehydrated. Dried gel pieces were rehydrated with 25 m[m]{.smallcaps} ammonium bicarbonate (pH 8.0) containing 10 μg/ml trypsin (Promega, Madison, WI) and incubated for 18 h at 37 °C. Tryptic peptide mixtures were extracted with 50% acetonitrile in 5% formic acid and concentrated in a speed vacuum concentrator for LC-MS/MS.

#### LC-MS/MS

An ion trap mass spectrometer (HCT, Bruker Daltonics, Bremen, Germany) coupled with an Ultimate 3000 nano-HPLC system (Dionex, Sunnyvale, CA) was used for LC-MS/MS data acquisition. A PepMap100 C-18 trap column (300 μm × 5 mm) and PepMap100 C-18 analytic column (75 μm × 150 mm) were used for reverse phase chromatographic separation with a flow rate of 300 nl/min. The two buffers used for the reverse phase chromatography were 0.1% formic acid/water (buffer A) and 0.08% formic acid/acetonitrile (buffer B), with a 125 min gradient (4--30% B for 105 min, 80% B for 5 min, and 4% B for 15 min). Eluted peptides were then directly sprayed into the mass spectrometer to record peptide spectra over the mass range of *m*/*z* 350--1500 and MS/MS spectra in information-dependent data acquisition over the mass range of *m*/*z* 100--2800. Repeatedly, MS spectra were recorded followed by three data-dependent CID MS/MS spectra generated from four highest intensity precursor ions. The MS/MS spectra were interpreted with the Mascot search engine (Matrix Science, London, UK). Database searches through Mascot, were performed with a mass tolerance of 0.5 Da, a MS/MS tolerance of 0.5 Da, and three missing cleavage site. In addition, carbamidomethylation on cysteine, oxidation on methionine, deamidation on asparagine/glutamine, and phosphorylation on serine/threonine were allowed for database searches.

#### Statistics

All data were statistically evaluated using one-way ANOVA followed by a Tukey\'s post hoc test unless otherwise stated. Significance was established upon a *p* value \< 0.05.

RESULTS
=======

### 

#### αCaMKII Interacts with Dopamine Transporter in Native Brain Preparations

A direct interaction of αCaMKII with the carboxyl terminus of human DAT was previously documented in a heterologous expression system *in vitro* ([@B13]). We examined this interaction *ex vivo* using corpora striata prepared from WT and αCaMKII-KO mice ([@B17]). DAT was immunopurified with an anti-DAT antibody from striatum. The immunoprecipitate prepared from WT striatal tissue contained immunoreactivity for αCaMKII, which was absent in immunoprecipitates from αCaMKII-deficient striata ([Fig. 1](#F1){ref-type="fig"}*a*). This was confirmed by mass spectrometry ([Fig. 1](#F1){ref-type="fig"}, *b--d*; [supplemental Fig. 1](http://www.jbc.org/cgi/content/full/M112.367219/DC1)).

![**αCamKII co-precipitates with DAT from mouse striatum.** *a*, αCamKII co-immunoprecipitates with DAT from WT but not αCaMKII-KO striatal lysates. Synaptosomal fractions were solubilized (*input*) and immunoprecipitated (*IP*) by an affinity purified polyclonal anti-DAT antibody. Co-purified αCamKII was detected with a monoclonal anti-αCaMKII antibody. *b*, Coomassie Blue-stained denaturing gel of striatal tissues prepared from WT and αCaMKII-KO mice with protein complex immunopurified by an anti-DAT antibody. LC-MS/MS identified DAT and βCamKII in immunopurified protein complex from WT and αCaMKII-KO mice and αCamKII only from WT mice. *c*, the double-charged (2^+^) MS/MS-spectrum obtained at *m*/*z* 567.33 was fragmented to produce a tandem mass spectrum with *y*- and *b*-ion series that identified the sequence AYLSVDFYR (amino acids 295--303) from mouse DAT. *d*, specific peptides of αCamKII and βCamKII (*e*) in immunoprecipitates from WT and αCaMKII-KO mice. The MS/MS spectrum at *m*/*z* 631.37 (2^+^) showing FYFENLWSR of αCamKII was identified only in association with the DAT of WT mice. *e*, the MS/MS spectrum at *m*/*z* 810.94 (2^+^) assigns the sequence FTDEYQLYEDIGK to βCamKII in immunoprecipitates from αCaMKII-KO mice.](zbc0381221290001){#F1}

We also investigated whether DAT and αCaMKII co-localized in primary dopaminergic neurons. For that purpose, we cultured ventral midbrain neurons from newborn pups and fixed and stained the neurons using specific antibodies against αCaMKII and DAT. Confocal imaging revealed co-staining for both αCaMKII and DAT, such as would be anticipated were these two proteins to interact ([Fig. 2](#F2){ref-type="fig"}*a*).

![**Co-localization of αCaMKII and DAT in primary dopaminergic neurons and expression levels of αCaMKII in WT, αCaMKII-KO, and αCaMKIIT^T305D^ mice.** *a*, αCamKII and DAT co-localize in primary dopaminergic neurons. Midbrain neurons were fixed with 4% PFA and stained with monoclonal antibodies against αCamKII and DAT, followed by fluorescently labeled secondary antibodies. Images were recorded using a Zeiss LSM510 microscope. *b*, representative immunoblot for αCamKII in WT, αCamKII-KO (KO), and αCamKII^T305D^ (*D*) striatal synaptosomes. Tubulin was used as a loading control. *c*, αCamKII bands were quantified by band densitometry and normalized to tubulin loading (*n* = 5 per genotype). *n.d.*, not detected. Statistically significant differences were assessed with a one-way ANOVA followed by Tukey\'s test. \*\*\*, *p* \< 0.001 of αCaMKII^T305D^ against WT.](zbc0381221290002){#F2}

#### Amphetamine-induced DAT-mediated Efflux Is Attenuated in αCaMKII Mutant Mice

Fog *et al.* ([@B13]) reported that the binding of αCaMKII to DAT and its subsequent phosphorylation of the DAT amino terminus supports the action of amphetamines. Accordingly, a consistent and statistically significant reduction in amphetamine-induced efflux of the DAT substrate 1-methyl \[^3^H\]-4-phenylpyridinium (\[^3^H\]MPP^+^) was observed upon the comparison of either superfused striatal synaptosomes or slices prepared from αCaMKII-KO to those prepared from WT mice ([Fig. 3](#F3){ref-type="fig"}, *a* and *b*).

![**Amphetamine-triggered substrate efflux in αCamKII mutant mice.** *a*, striatal synaptosomes prepared from wild-type (WT) and αCaMKII-KO (KO) mice were preloaded with \[^3^H\]MPP^+^ (0. 1 μCi) for 20 min, loaded onto Whatman GF/B filters, and superfused. A stable base line was established by continuous superfusion for 40min. Thereafter, at time = 0 min, six fractions were collected. Basal efflux amounted to 2.47 ± 0.03% min^−1^, *i.e.* 771 ± 19 dpm min^−1^ (*n* = 144). At time = 10 min, [d]{.smallcaps}-amphetamine (6 μ[m]{.smallcaps}) was added to the buffer and at time = 20 min, filters were lysed, and remaining radioactivity was determined. Data are presented as fractional efflux, *i.e.* each fraction is expressed as the percentage of radioactivity present in the synaptosomes at the beginning of that fraction. Symbols represent means ± S.E. of five observations performed in triplicate. ANOVA with Bonferroni correction \*\*\*, *p* \< 0.001. *b*, AUC values determined from superfusion experiments assessing synaptosomes prepared from different mice as indicated. Statistically significant differences were assessed with a one-way ANOVA followed by Tukey\'s test. \*\*\*, *p* \< 0.001 of αCaMKII-KO against WT; \*, *p* \< 0.05 of αCaMKII^T305D^ (*D*) against WT. *c*, striatal slices from WT, αCaMKII-KO (KO), and αCaMKII^T305D^ (*D*) mice were prepared as described under "Experimental Procedures." AUC of [d]{.smallcaps}-amphetamine-induced efflux was calculated. Statistically significant differences were assessed with a one-way ANOVA followed by Tukey\'s test. \*\*, *p* \< 0.01 of αCaMKII-KO (KO) against WT, respectively. \*, *p* \< 0.05 of αCaMKII^T305D^ (*D*) against WT. *d*, AUC values determined from superfusion experiments assessing synaptosomes prepared from WT mice in the presence of KN93 (15 μ[m]{.smallcaps}) or AIP (0.1 μ[m]{.smallcaps}, 1 μ[m]{.smallcaps}) as indicated. Statistically significant differences were assessed with a one-way ANOVA followed by Tukey\'s test. \*, *p* \< 0.05 of drug treatment against control (dimethyl sulfoxide; *DMSO*) (*n* = 3--5).](zbc0381221290003){#F3}

We examined whether αCaMKII activity itself is required in addition to αCaMKII binding to the DAT ([@B13]) by using the αCaMKII^T305D^ mutant, which carries a threonine to aspartate mutation in the calcium/calmodulin binding domain. This amino acid substitution mimics inhibitory autophosphorylation at Thr-305 and renders (i) the αCaMKII protein inactive ([@B17]) and (ii) lowers the expression level in the striatum ([Fig. 2](#F2){ref-type="fig"}, *b* and *c*) and hippocampus ([@B17]). We observed that the amphetamine-induced release in αCaMKII^T305D^ mice was significantly decreased and was therefore comparable to that seen in αCaMKII-KO mice ([Fig. 3](#F3){ref-type="fig"}, *b* and *c*). However, there was no significant difference between the basal \[^3^H\]MPP^+^ efflux levels (wild-type, 5.2 ± 0.4 fmol/2 min; αCaMKII-KO, 4.3 ± 0.4 fmol/2 min; αCaMKII^T305D^, 4.8 ± 0.2 fmol/2 min (*n* = 5) according to repeated measures ANOVA, followed by Tukey\'s post hoc tests). Hence, these results suggest that DAT activity requires not only αCaMKII binding but also its activation. To test whether the remaining DAT activity observed in our experiments was due to the activity of βCaMKII, which was also detected in DAT immunoprecipitates after MS/MS analysis ([Fig. 1](#F1){ref-type="fig"}, *b--e*), we superfused striatal synaptosomes of WT and αCaMKII-KO mice in the presence of the general CaMKII inhibitor KN93. Amphetamine-induced release in synaptosomes obtained from WT mice was significantly reduced by KN93 (15 μ[m]{.smallcaps}; AUC~WT,Co~, 47 ± 1.3% (*n* = 6); AUC~WT,KN93~, 31.6 ± 2.7% (*n* = 13, *p* \< 0.01) but similar to that observed in synaptosomes of αCaMKII-KO mice (AUC~KO,Co~, 31.8 ± 1.3%; *n* = 23). In addition, KN93 did not have any appreciable effect on synaptosomes of αCaMKII-KO (AUC~KO,KN93~, 35.0 ± 1.8%; *n* = 10).

In an additional set of experiments, the more specific CaMKII inhibitor AIP (autocamtide-2-related inhibitory peptide II) was compared with KN93 ([@B21]). In accordance with the data described above, DAT-mediated efflux from striatal synaptosomes (WT mice) was reduced by AIP in a concentration-dependent manner and thus supported the findings with KN93 ([Fig. 3](#F3){ref-type="fig"}*d*). The results thus demonstrate that amphetamine-induced efflux via the DAT is (i) contingent on a functional copy of αCaMKII, and (ii) βCamKII cannot substitute for αCaMKII and thereby sustain DAT efflux activity, although βCamKII also precipitates with DAT ([Fig. 1](#F1){ref-type="fig"}, *d* and *e*; [supplemental Fig. 1](http://www.jbc.org/cgi/content/full/M112.367219/DC1)).

#### DAT Expression Remains Unchanged in αCaMKII Mutant Mice

Differences in release cannot be accounted for by variations in DAT levels in the striata of the mice because the DAT expression was unchanged as assessed by three independent approaches: (i) uptake of \[^3^H\]MPP^+^ into striatal synaptosomes (WT, 3.6 ± 0.3 fmol/mg/min; αCaMKII-KO, 3.3 ± 0.6 fmol/mg/min; αCaMKII^T305D^, 3.1 ± 0.2 fmol/mg/min (*n* = 4 per genotype); [Fig. 4](#F4){ref-type="fig"}*a*); (ii) high-affinity binding of the dopamine reuptake inhibitor \[^3^H\]CFT to striatal membranes (*K~d~*, 10.4 ± 4.7 n[m (wt)]{.smallcaps}; 15.7 ± 4.8 n[m]{.smallcaps} (αCaMKII-KO); 9.4 ± 1.4 n[m]{.smallcaps} (αCaMKII^T305D^); B~max~, 0.087 ± 0.015 pmol/mg wet weight (WT); 0.115 ± 0.016 pmol/mg wet weight (αCaMKII-KO); 0.077 ± 0.004 pmol/mg wet weight (αCaMKII^T305D^) (*n* ≥ 3 per genotype; [Fig. 4](#F4){ref-type="fig"}*b*), and (iii) the surface biotinylation of striatal DAT protein ([Fig. 4](#F4){ref-type="fig"}, *c* and *d*). Thus, our data reveal that αCaMKII interacts with DAT in native brain preparations and that its activity plays a major role in supporting amphetamine-induced efflux.

![**DAT expression in αCamKII mutant mice.** *a*, uptake of \[^3^H\]MPP^+^ in mouse striatal synaptosomes prepared from the following mice: wild-type (WT), αCaMKII knock-out (KO), αCaMKII^T305D^ (*D*). Experiments were performed four times in triplicate. *b*, binding of \[^3^H\]CFT to membranes prepared from corpora striata of wild-type, αCaMKII-KO (KO), αCaMKII^T305D^ (*D*). Membranes were incubated with \[^3^H\]CFT (concentrations as indicated) in the presence of Zn^2+^ (10 μ[m]{.smallcaps}) for 10 min (22 °C; V = 200 μl). Nonspecific binding was defined in the presence of 3 μ[m]{.smallcaps} methylphenidate and was \<5% at a concentration corresponding to *K~D~. c*, surface biotinylation of DAT. Shown in the *upper panel* are surface-biotinylated samples of three different mouse strains: WT, αCaMKII-KO, αCaMKII^T305D^ (*D*). The *lower panel* shows DAT from total extracts. Densitometric evaluation of three experiments revealed comparable values relative to wild-type expression. *d*, bands were quantified by band densitometry and normalized to total DAT bands (*n* = 3 per genotype). No significant differences were assessed (one-way ANOVA followed by Tukey\'s test).](zbc0381221290004){#F4}

#### Angelman Syndrome Mice Display Impaired Amphetamine-triggered DAT Efflux

Angelman syndrome is caused by the loss of functional E3 ubiquitin ligase Ube3A, which renders αCaMKII less active due to increased phosphorylation at the inactivating αCaMKII Thr-305/Thr-306 sites ([@B22]). Our experiments indicate that αCaMKII activity is required to regulate reverse transport by DAT, which may subsequently affect dopaminergic signaling ([@B23]); thus, we hypothesized that DAT function is impaired in Angelman syndrome. Accordingly, we examined Ube3A^p+/m−^ mice (also known as Angelman syndrome mice), a mouse model of Angelman syndrome, ([@B15]) for a potential deficit in DAT function. Initially, we examined whether αCaMKII was still able to bind DAT in these mice by co-immunoprecipitation. αCaMKII was co-purified with DAT in both WT and Angelman syndrome mice. ([Fig. 5](#F5){ref-type="fig"}, *a* and *b*).

![**DAT immunoprecipitation and αCamKII expression in Angelman syndrome mice.** *a*, αCamKII co-immunoprecipitates with DAT from wild-type (WT) and Angelman syndrome (AS) mouse striatal lysates. Synaptosomal fractions were solubilized (*input*) and immunoprecipitated (*IP*) by an affinity purified polyclonal anti-DAT antibody. Co-purified αCamKII was detected with a monoclonal anti-αCaMKII antibody. *b*, control for immunoprecipitation efficiency of samples from *a. c*, representative immunoblot for αCamKII in WT and AS striatal synaptosomes. Tubulin was used as a loading control. *d*, αCamKII bands were quantified by band densitometry and normalized to tubulin loading (*n* = 4 per genotype). No significant differences between WT and AS were assessed (Student\'s *t* test).](zbc0381221290005){#F5}

Additionally, we assessed the total protein levels of αCaMKII in the striatum and found no significant difference ([Fig. 5](#F5){ref-type="fig"}, *c* and *d*). We assessed amphetamine-induced efflux in Angelman syndrome mice as outlined above and compared striatal synaptosomes of Angelman syndrome mice to those of WT mice ([Fig. 6](#F6){ref-type="fig"}*a*). Interestingly, basal \[^3^H\]MPP^+^ efflux levels were significantly higher in Angelman syndrome mice compared with WT mice (WT = 2.2 ± 0.1 fmol/2min, Angelman syndrome mice = 2.8 ± 0.02 fmol/2min; *n* = 5; *p* \< 0.01, paired Student\'s *t* test, two-tailed); this finding was in contrast to the observations in αCaMKII mutant mice, which were slightly lower compared with WT mice (see above).

![**Amphetamine-induced efflux and DAT expression in Angelman syndrome mice.** *a*, AUC values of amphetamine-induced \[^3^H\]MPP^+^ efflux determined from superfusion experiments of synaptosomes (WT, wild-type and AS, Angelman syndrome). Basal efflux amounted to 2.39 ± 0.03% min^−1^, *i.e.* 629 ± 15 dpm min^−1^; *n* = 144. Statistically significant differences were assessed by Student\'s *t* test. \*\*, *p* \< 0.01 of AS against WT. *b*, DAT cell surface biotinylation. Shown in the *upper panel* is surface-biotinylated DAT in wild-type and AS mice. The *lower panel* shows DAT from total extracts. *c*, bands were quantified by band densitometry and normalized to total DAT (*n* = 3 per genotype). No significant differences between WT and AS were assessed (Student\'s *t* test). *d*, binding of \[^3^H\]CFT to membranes prepared from WT and AS striata. Membranes (0.15 mg wet weight) were incubated with \[^3^H\]CFT (concentrations as indicated) in the presence of Zn^2+^ (10 μ[m]{.smallcaps}) for 10min (22 °C; V = 200 μl). Nonspecific binding was defined in the presence of 3 μ[m]{.smallcaps} methylphenidate and was \<5% at the *K~D~* concentration (*n* = 3). *e*, uptake of \[^3^H\]MPP^+^ in striatal synaptosomes prepared from the following mice: WT and AS. Experiments were performed three times in triplicate.](zbc0381221290006){#F6}

DAT expression in Angelman syndrome and WT mice was also investigated: surface biotinylation, uptake, and binding experiments ([Fig. 6](#F6){ref-type="fig"}, *b--e*) verified that DAT was present at comparable levels and mediated substrate uptake at similar rate (uptake: WT, 2.3 ± 0.5 fmol/mg/min; Angelman syndrome, 2.5 ± 0.3 fmol/mg/min (*n* = 3 per genotype); binding: *K~d~* WT, 10.3 ± 5.2 n[m]{.smallcaps}; Angelman syndrome, 8.6 ± 3.0 n[m]{.smallcaps}; B~max~ WT, 0.101 ± 0.02 pmol/mg wet weight; Angelman syndrome, 0.098 ± 0.012 pmol/mg wet weight (*n* = 3 per genotype); [Fig. 6](#F6){ref-type="fig"}, *b--e*). However, the amphetamine-induced efflux of \[^3^H\]MPP^+^ was significantly reduced in striatal synaptosomes from Angelman syndrome mice ([Fig. 6](#F6){ref-type="fig"}*a*). This observation is consistent with the results obtained in the αCaMKII-KO and αCaMKII^T305D^ mice.

DISCUSSION
==========

Unraveling the mechanisms of DAT function and regulation is vital to the understanding of a variety of neuropsychiatric disorders, ranging from Parkinson disease to attention deficit hyperactivity disorder and drug addiction. The recently identified interaction of DAT and αCaMKII prompted us to investigate whether or not the disturbance of this DAT-interacting protein has consequences on DAT function.

Angelman syndrome is caused by a loss of function mutation in Ube3A, a HECT (homologous to E6 carboxyl terminus) domain containing E3 ubiquitin ligase ([@B14]). Ube3A is normally expressed in a biallelic fashion in most tissues; however, in the brain, it is mainly expressed from the maternal allele ([@B24]). The maternal loss of Ube3A causes increased phosphorylation of αCaMKII at Thr-286 and Thr-305/Thr-306 by means that are currently unknown, thereby rendering αCaMKII self-inhibited ([@B16]) ([@B25]). The resulting Angelman syndrome is characterized by severe developmental delay, including impaired motor coordination and language deficits ([@B26]). The identification of the molecular basis of Angelman syndrome pathophysiology is a subject of immense interest as there is currently no targeted drug therapy available to treat human Angelman syndrome patients ([@B27]). Recently, it has been unraveled that the unsilencing of the paternal Ube3a allele using topoisomerase inhibitors might be beneficial for the treatment of Angelman syndrome patients ([@B28]). Other possible treatment options attempt to target the dopaminergic system. Therefore, we investigated whether the previously reported interaction between αCaMKII and DAT ([@B13]) is of pathophysiological importance in Angelman syndrome. We used Ube3A^p+/m−^ mice, a mouse model of Angelman syndrome, to assess whether the self-inhibition of αCaMKII observed in these mice affects the functionality of the DAT. We examined DAT-mediated uptake and amphetamine-induced substrate efflux in Angelman syndrome mice. As controls, we performed experiments in mice lacking αCaMKII (αCaMKII-KO mice) as well as mice in which αCaMKII function is inhibited by a point mutation at Thr-305 (αCaMKII^T305D^ mice). This mutant mimics the auto-phosphorylation of this residue, which is known to inactivate the kinase ([@B17]).

Our experiments show that amphetamine-induced DAT-mediated substrate efflux but not basal efflux is significantly attenuated in αCaMKII-KO and αCaMKII^T305D^ mutant mice. This decrease is a consequence of blunted αCaMKII function and not due to changes in DAT protein expression as substrate uptake, radioligand binding, and surface biotinylation did not reveal any significant changes in mutants compared with the wild-type upon acute exposure to amphetamine.

In contrast, a longer exposure to amphetamines regulates CaMKII activity and DAT function in a different manner: a 30-min amphetamine treatment of HEK293-hDAT cells stimulates CaMKII activity profoundly and initiates a decrease in Akt activity, which, in turn, results in a subsequent down-regulation of DAT surface expression ([@B29]). In addition, syntaxin 1A, a member of the family of soluble *N*-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins has been shown to directly interact with monoamine transporters and regulate their function ([@B30]). CaMKII activity is required for an amphetamine-induced association between DAT and syntaxin 1A, which thereby increased amphetamine-induced substrate efflux ([@B31]).

Our experiments suggest that DAT is among the proteins affected by disturbed maternal Ube3A and this deficiency is most likely caused by inhibited αCaMKII. In fact, some clinical features of Angelman syndrome are plausibly explained by an impaired connection of αCaMKII and the defective Ube3A protein, which finally impacts on DAT function. The dopaminergic system plays a major role in both movement disorders ([@B32]) and autism ([@B33]), both of which are key manifestations of the Angelman syndrome phenotype in human patients ([@B26]). Based on our observations, it is tempting to speculate that an anomalous function of DAT may account for some of the manifestations of Angelman syndrome. Two possibilities for anomalous function of DAT should be taken into consideration: (i) in the case of Angelman syndrome, it is plausible that the disease arises from a defective interactome comprised of αCaMKII and the Ube3A protein; (ii) alternatively, anomalous function may also be ascribed to DAT itself, for *e.g.* the coding variant DAT^A559V^, previously identified in a pedigree of male attention deficit hyperactivity disorder patients mediated exaggerated efflux ([@B34]). Whether or not anomalous dopamine efflux occurs via either one of these two possibilities, it certainly bears a marked pathophysiological relevance: efflux via DAT regulates dopaminergic signaling because released dopamine binds to dopamine D~2~ receptors, which are in close association with DAT ([@B35], [@B36]). Stimulation of D~2~ receptors increases DAT surface expression by an ERK1/2-dependent process ([@B35]), and increased DAT uptake has been implicated with states of hyperinsulinemia ([@B37], [@B38]). This, in turn, suggests that insulin signaling pathways may regulate dopamine transmission and thereby significantly influence the effects exerted by amphetamines.

In line with these observations, D~2~ receptors are tonically activated in cells expressing the mutant DAT^A559V^ and thereby support the anomalous dopamine efflux via DAT^A559V^ ([@B36]). Furthermore, the hypothesis that dopaminergic signaling may be modulated by dopamine released from presynaptic sites via DAT has been fueled by observations made during electrophysiological and amperometric recordings in rat brain slices ([@B23]). Consistent with a role of DAT in Angelman syndrome, Ube3A^p+/m−^ mice become hypodopaminergic and develop motor deficits that are equivalent to human Parkinson disease ([@B39]). In fact, frank (levodopa responsive) Parkinson disease has also been observed in young adults with Angelman syndrome ([@B40]). Hence, our data on DAT-mediated efflux in striata prepared from Angelman syndrome mice establishes an association between defective Ube3A and DAT and indicates that a defective αCaMKII is most likely the link between these two proteins.
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